Advanced search    

Search: authors:"James E Galvin"

19 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Sarcopenic obesity and cognitive performance

University , Boca raton, Fl, UsA , USA 2 James e galvin PowerdbyTCPDF(ww.tcpdf.org) stephanie Chrisphonte 1 Background: Sarcopenia and obesity both negatively impact health including cognitive function. Their

Lewy Body Dementia Association’s Research Centers of Excellence Program: Inaugural Meeting Proceedings

National Institutes of Health (NIH) and the Michael J. Fox Foundation. James E Galvin has received grant support from NIH, Michael J Fox Foundation, Harry T. Mangurian Foundation, Lewy Body Dementia

Cognitive impairment in Parkinson’s disease: a report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health

Beth A. Vernaleo 10 Richard Camicioli 11 Nabila Dahodwala 12 Roseanne D. Dobkin 13 Terry Ellis 14 James E. Galvin 15 Connie Marras 16 Jerri Edwards 17 Julie Fields 19 Robyn Golden 0 Jason Karlawish 1

Longitudinal Associations between Physical and Cognitive Performance among Community-Dwelling Older Adults

To assess the directionality of the association between physical and cognitive decline in later life, we compared patterns of decline in performance across groups defined by baseline presence of cognitive and/or physical impairment [none (n = 217); physical only (n = 169); cognitive only (n = 158), or both (n = 220)] in a large sample of participants in a cognitive aging study at...

Lewy body dementia: the impact on patients and caregivers

Lewy body dementia (LBD) is the second most common neurodegenerative dementia in older adults, yet there remains a delay in diagnosis that limits healthcare providers’ ability to maximize therapeutic outcomes and enhance patient and caregiver quality of life. The impact of LBD on patients includes limiting the potential exposure to medications that may cause adverse outcomes, and...

Update on Dementia with Lewy Bodies

Stella Karantzoulis 0 James E. Galvin 0 0 J. E. Galvin Comprehensive Center on Brain Aging and Departments of Neurology and Psychiatry, New York University Langone Medical Center , New York, NY, USA ... for the Lewy Body Composite Risk Score. Compliance with Ethics Guidelines Conflict of Interest Stella Karantzoulis and James E. Galvin declare that they have no conflict of interest. Human and Animal

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch

Grossberg 1 James E Galvin 7 Jeffrey L Cummings 5 6 Tillmann Krahnke 4 Christine Strohmaier 4 0 Alzheimer's Disease and Other Cognitive Disorders Unit, ICN, Hospital Clínic i Universitari, IDIBAPS

Negotiating the Joint Career: Couples Adapting to Alzheimer's and Aging in Place

To understand the impact of memory loss on aging in place, this paper investigated dyads where one spouse had been diagnosed with memory loss. In-depth qualitative interviews were conducted with ten couples (N=20). Grounded theory methods were used to collect, code, and analyze data into themes. Data revealed consensus among and between dyads that it was best to focus on living...

Negotiating the Joint Career: Couples Adapting to Alzheimer's and Aging in Place

To understand the impact of memory loss on aging in place, this paper investigated dyads where one spouse had been diagnosed with memory loss. In-depth qualitative interviews were conducted with ten couples (N=20). Grounded theory methods were used to collect, code, and analyze data into themes. Data revealed consensus among and between dyads that it was best to focus on living...

The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis

Background The etiology of Parkinson disease (PD) has yet to be fully elucidated. We examined the consequences of injections of 3,4-dihydroxyphenylacetaldehyde (DOPAL), a toxic metabolite of dopamine, into the substantia nigra of rats on motor behavior and neuronal survival. Methods/Principal Findings A total of 800 nl/rat of DOPAL (1 µg/200 nl) was injected stereotaxically into...

Practical clinical tool to monitor dementia symptoms: the HABC-Monitor

Practical clinical tool to monitor dementia symptoms: the HABC-Monitor Patrick O Monahan,1 Malaz A Boustani,1–3,6 Catherine Alder,2,3,6 James E Galvin,7 Anthony J Perkins,2,3 Patrick Healey,4 Azita

The muscle protein dysferlin accumulates in the Alzheimer brain

Dysferlin is a transmembrane protein that is highly expressed in muscle. Dysferlin mutations cause limb-girdle dystrophy type 2B, Miyoshi myopathy and distal anterior compartment myopathy. Dysferlin has also been described in neural tissue. We studied dysferlin distribution in the brains of patients with Alzheimer disease (AD) and controls. Twelve brains, staged using the...

Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease

, Daniel Varon, Maria T. Greig, Peggy Roberts, Marilyn Albert, Chiadi Onyike, Daniel D’Agostino, Stephanie Kielb, James E. Galvin, Brittany Cerbone, Christina A. Michel, Dana M. Pogorelec, Henry Rusinek

Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns

Accumulating evidence suggests that Alzheimer’s disease (AD) is heterogenous and can be classified into several subtypes. Here, we propose a robust subtyping method for AD based on cortical atrophy patterns and graph theory. We calculated similarities between subjects in their atrophy patterns throughout the whole brain, and clustered subjects with similar atrophy patterns using...

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology

Roberts, Marilyn Albert, Chiadi Onyike, Daniel D’Agostino, Stephanie Kielb, James E. Galvin, Brittany Cerbone, Christina A. Michel, Henry Rusinek, Mony J. de Leon, Lidia Glodzik, Susan De Santi, P. Murali

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts

The Clusterin (CLU) gene, also known as apolipoprotein J (ApoJ), is currently the third most associated late-onset Alzheimer’s disease (LOAD) risk gene. However, little was known about the possible effect of CLU genetic variants on AD pathology in brain. Here, we evaluated the interaction between 7 CLU SNPs (covering 95% of genetic variations) and the role of CLU in β-amyloid (A...

Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis

Grossman, Effie Mitsis, Leyla de Toledo-Morrell, Raj C. Shah, Ranjan Duara, Daniel Varon, Maria T. Greig, Peggy Roberts, Marilyn Albert, Chiadi Onyike, Daniel D’Agostino, Stephanie Kielb, James E. Galvin

Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits

, Raymundo Hernando, Antero Sarrael, William Potter, Neil Buckholtz, John Hsiao, Smita Kittur, James E. Galvin, Brittany Cerbone, Christina A. Michel, Dana M. Pogorelec, Henry Rusinek, Mony J de Leon, Lidia

Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE

, Stephanie Kielb, James E. Galvin, Brittany Cerbone, Christina A. Michel, Henry Rusinek, Mony J de Leon, Lidia Glodzik, Susan De Santi, P. Murali Doraiswamy, Jeffrey R. Petrella, Terence Z. Wong, Steven E